HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Se‐Hoon Lee et al.|Journal of Clinical Oncology|2023Cited by 224
Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP78Zhiwen Gu, Aihua Sun, Lei Wang et al.|Proceedings of the National Academy of Sciences|2023Cited by 37
Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetesDianjun Sun, Ye‐Xuan Cao, Xinyu You et al.|Journal of Endocrinological Investigation|2018Cited by 15
OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01Helena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Thoracic Oncology|2023Cited by 1